Moderna's Stephen Hoge sells 39,145 shares on Oct. 15

Q: How many MRNA shares did Stephen Hoge acquire by exercising options?

Stephen Hoge exercised options for 76,453 shares on October 14, 2026, and 76,452 shares on October 15, 2026, at an exercise price of $12.21 per share on each date.

Q: How many MRNA shares did Stephen Hoge sell, and at what prices?

On October 14, 2026, Stephen Hoge sold 38,774 shares at a weighted average price of $213.47 and 450 shares at a weighted average price of $214.15. On October 15, 2026, he sold 39,145 shares at a weighted average price of $220.72.

Q: Were Stephen Hoge's exercised MRNA options vested?

Both reported options were fully vested and exercisable.

The reported transactions by Moderna's president were made under a Rule 10b5-1 plan adopted June 15, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Moderna, Inc. President Stephen Hoge exercised options for 76,453 shares on October 14, 2026, and 76,452 shares on October 15, 2026, at an exercise price of $12.21 per share. On October 14, he sold 38,774 shares at a weighted average price of $213.47 and 450 shares at a weighted average price of $214.15. On October 15, he sold 39,145 shares at a weighted average price of $220.72.

The transactions were effected under a Rule 10b5-1 trading plan adopted June 15, 2026. Separate indirect-holding entries dated October 14 listed 4,116 shares held by Valhalla, LLC and 151,933 shares held by a trust for Hoge’s spouse and children, of which his spouse is a trustee. Hoge disclaimed Section 16 beneficial ownership of the trust shares except to the extent of any pecuniary interest.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 9 txns

Insider Hoge Stephen

Role President

Sold 78,369 shs ($17.01M)

Approx. gross sale proceeds $17.01M

Approx. exercise cost $1.87M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F1, F6}	76,452	$0.00	$0.00
Exercise	Common Stock ^F1	76,452	$12.21	$933K
Sale	Common Stock ^{F1, F4}	39,145	$220.72	$8.64M
Exercise	Stock Option (Right to Buy) ^{F1, F6}	76,453	$0.00	$0.00
Exercise	Common Stock ^F1	76,453	$12.21	$933K
Sale	Common Stock ^{F1, F2}	38,774	$213.47	$8.28M
Sale	Common Stock ^{F1, F3}	450	$214.15	$96K
holding	Common Stock	--	--	--
holding	Common Stock ^F5	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 152,905 contracts (Direct); Common Stock — 1,636,565 shares (Direct); Common Stock — 4,116 shares (Indirect, By Valhalla, LLC); Common Stock — 151,933 shares (Indirect, By Trust)

Footnotes (6)

F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.
F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $213.03 to $213.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $214.05 to $214.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $220.60 to $221.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5. These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F6. This option is fully vested and exercisable.

Key Figures

Option exercise: 76,453 shares; $12.21 exercise price per share Option exercise: 76,452 shares; $12.21 exercise price per share Shares sold: 38,774 shares at a weighted average price of $213.47 per share +4 more

7 metrics

Option exercise 76,453 shares; $12.21 exercise price per share October 14, 2026

Option exercise 76,452 shares; $12.21 exercise price per share October 15, 2026

Shares sold 38,774 shares at a weighted average price of $213.47 per share October 14, 2026

Shares sold 450 shares at a weighted average price of $214.15 per share October 14, 2026

Shares sold 39,145 shares at a weighted average price of $220.72 per share October 15, 2026

Trust-held shares 151,933 shares Indirect holding listed October 14, 2026; trust for Hoge's spouse and children

Valhalla, LLC-held shares 4,116 shares Indirect holding listed October 14, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, fully vested and exercisable

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested and exercisable technical

"This option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MRNA shares did Stephen Hoge acquire by exercising options?

Stephen Hoge exercised options for 76,453 shares on October 14, 2026, and 76,452 shares on October 15, 2026, at an exercise price of $12.21 per share on each date.

How many MRNA shares did Stephen Hoge sell, and at what prices?

On October 14, 2026, Stephen Hoge sold 38,774 shares at a weighted average price of $213.47 and 450 shares at a weighted average price of $214.15. On October 15, 2026, he sold 39,145 shares at a weighted average price of $220.72.

Were Stephen Hoge's exercised MRNA options vested?

Both reported options were fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/16/2026 - 04:09 PM EDT Accepted by SEC EDGAR 10/16/2026 - 04:09 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoge Stephen

(Last)

(First)

(Middle)

C/O MODERNA, INC.

325 BINNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/14/2026		M⁽¹⁾		76,453	A	$12.21	1,638,482	D
Common Stock	10/14/2026		S⁽¹⁾		38,774	D	$213.47⁽²⁾	1,599,708	D
Common Stock	10/14/2026		S⁽¹⁾		450	D	$214.15⁽³⁾	1,599,258	D
Common Stock	10/15/2026		M⁽¹⁾		76,452	A	$12.21	1,675,710	D
Common Stock	10/15/2026		S⁽¹⁾		39,145	D	$220.72⁽⁴⁾	1,636,565	D
Common Stock								4,116	I	By Valhalla, LLC
Common Stock								151,933	I	By Trust⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$12.21	10/14/2026		M⁽¹⁾			76,453	⁽⁶⁾	02/23/2027	Common Stock	76,453	$0	229,357	D
Stock Option (Right to Buy)	$12.21	10/15/2026		M⁽¹⁾			76,452	⁽⁶⁾	02/23/2027	Common Stock	76,452	$0	152,905	D

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $213.03 to $213.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $214.05 to $214.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $220.60 to $221.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

5. These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

6. This option is fully vested and exercisable.

	/s/ James Dillon, as Attorney-in-Fact	10/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR